Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 425-270-0 | CAS number: 134620-00-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 14 August 1996 to 12 March 1997
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Referenceopen allclose all
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 997
- Report date:
- 1997
- Reference Type:
- other: Commentary
- Title:
- Unnamed
- Year:
- 1 997
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Tetrammine Palladium Hydrogen Carbonate
- IUPAC Name:
- Tetrammine Palladium Hydrogen Carbonate
- Reference substance name:
- 134620-00-1
- Cas Number:
- 134620-00-1
- IUPAC Name:
- 134620-00-1
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- - Name of test material (as cited in study report): tetrammine palladium hydrogen carbonate
- Substance type: no data
- Physical state: pale yellow solid
- Analytical purity: no data
- Impurities (identity and concentrations): no data
- Composition of test material, percentage of components: no data
- Isomers composition: no data
- Purity test date: no data
- Lot/batch No.: DF0445
- Expiration date of the lot/batch: no data
- Stability under test conditions: formulations prepared weekly were stable for at least 10 days
- Storage condition of test material: compound stored at room temperature, shielded from light; formulations stored at approximately 4 °C, in the dark
Constituent 1
Constituent 2
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Limited, Manston, Kent
- Age at study initiation: 5-6 weeks
- Weight at study initiation: males: 166 to 224 g; females: 144 to 189 g
- Fasting period before study: no data
- Housing: groups of 5 in polypropylene grid-floor cages
- Diet (e.g. ad libitum): ad libitum standard pellet diet
- Water (e.g. ad libitum): ad libitum mains water
- Acclimation period: 11 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 ± 2
- Humidity (%): 55 ± 15
- Air changes (per hr): at least 15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: 24 September 1996 to 6 November 1996
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: prepared weekly
VEHICLE
- Concentration in vehicle: 0, 0.15, 1.5 or 15 mg/ml
- Amount of vehicle (if gavage): 10 ml
- Purity: no data - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Theoretical test material concentrations of 0.15, 1.5 or 15 mg/ml (in distilled water) were analysed via high performance liquid chromatography (HPLC). To determine homogeneity, the top, middle and bottom of the samples were assessed. Stability was evaluated by testing 10 days after formulating. Concentrations of weekly test material formulations were assessed on weeks 1-4, with concentrations found to range between 94 and 107% of the nominal value.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Once daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
1.5, 15 or 150 mg/kg bw/day
Basis:
other: nominal
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: based on the results of a 14-day range-finding study on 3/sex/dose of the same rat strain, given 0, 15, 150 or 400 mg/kg bw/day
- Positive control:
- No positive control
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: animals were observed for mortality and overt clinical signs of toxicity immediately before dosing and one and five hours after dosing during the working week, and observed immediately before dosing and one hour after dosing on weekends
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: day 0 (the day before the start of treatment), 7, 14, 21 and 28, and at terminal kill (day 29).
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes, weekly
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No
FOOD EFFICIENCY: Yes
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
- Time schedule for examinations: daily (overt changes only)
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at the end of the study (day 28)
- Anaesthetic used for blood collection: No data
- Animals fasted: No
- How many animals: all test and control animals
- Parameters checked in table No.1 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at the end of the study (day 28)
- Animals fasted: No
- How many animals: all test and control animals
- Parameters checked in table No.1 were examined.
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table 2)
HISTOPATHOLOGY: Yes (see table 2) - Other examinations:
- No other examinations performed
- Statistics:
- One-way analysis of variance (ANOVA) was used to compare absolute and relative organ weights, haematological and clinical chemistry data, incorporating the F-max test for homogeneity of variance. The Kruskal-Wallis and Mann Whitney non-parametric ANOVA tests were used on data showing heterogeneous variances.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- During week 3, reduced growth was seen in males and females given 150 mg/kg bw/day
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- During week 3, reduced food consumption was seen in males given 150 mg/kg bw/day
- Food efficiency:
- effects observed, treatment-related
- Description (incidence and severity):
- During week 3, reduced food efficiency was seen in males given 150 mg/kg bw/day
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Reduced haemoglobin, erythrocyte count, haematocrit and mean corpuscular volume in males given 150 mg/kg bw/day. Two of these males had unusually high reticulocyte counts. Slight but significant rise in eosinophil levels in females given 150 mg/kg bw/day
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Increased absolute and relative kidney weights in females given 150 mg/kg bw/day
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Pallor of the liver, kidneys and glandular gastric epithelium seen in one male given 150 mg/kg bw/day; reddening of the glandular gastric epithelium seen in one female given 150 mg/kg bw/day
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Microscopic changes seen in the spleens of females given 15 mg/kg bw/day, and in the liver, spleen, kidneys and stomach of males and females given 150 mg/kg bw/day. Increased mucus-secreting Goblet cells in glandular gastric mucosa of a 15 mg/kg bw/d male
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY:
No unscheduled deaths or toxicologically-relevant clinical signs of toxicity seen during the study.
Animals given 150 mg/kg bw/day showed increased salivation before or immediately after dosing from day 14, and sporadic incidences of increased salivation one hour after dosing, and noisy respiration. These effects were considered to result from an unpalatable and/or locally irritating formulation, or the dosing procedure, rather than compound-related systemic toxicity.
BODY WEIGHT AND WEIGHT GAIN: See table 3 for details.
Reduced growth seen in males and females given 150 mg/kg bw/day during study week 3, compared to controls. One of the males showed a slight body weight loss on day 21. Growth was similar to controls during the final week of the experiment.
FOOD CONSUMPTION AND COMPOUND INTAKE:
21% decrease in food consumption in males given 150 mg/kg bw/day during study week 3 (mean 164 g/rat), compared to controls (mean 207 g/rat). Food efficiency also reduced in these males (mean 6%, compared to 15% in controls).
WATER CONSUMPTION AND COMPOUND INTAKE:
No significant effects seen.
HAEMATOLOGY: See table 4 for details.
Reduced haemoglobin, erythrocyte count, haematocrit and mean corpuscular volume in males given 150 mg/kg bw/day. The changes were not statistically significant, but many individual values fell outside the normally-expected range for rats of this age and strain. Two of these males also had unusually high reticulocyte counts. High-dose females showed a slight, but statistically significant, increase in eosinophil count, with two individual values outside the normally expected range. Other effects were not considered to be toxicologically significant.
Males given 150 mg/kg bw/day exhibited a slight, but statistically significant, increase in mean corpuscular haemoglobin concentration, but all individual values were within the normally expected range for rats of this age and strain. A slight, but significant, increase in lymphocyte count was seen in males given 15 or 150 mg/kg bw/day, but the highest individual value was seen in the 15 mg/kg bw/day group, making a dose-response relationship negligible.
Females given 150 mg/kg bw/day exhibited a slight, but statistically significant, increase in platelet count, but, in the absence of other associated changes indicating an adverse effect, this was considered to have arisen by chance.
CLINICAL CHEMISTRY: See table 4 for details.
No toxicologically significant changes in blood chemical parameters measured.
Males given 150 mg/kg bw/day showed a significant reduction in total plasma protein, a slightly increased plasma albumin/globulin ratio, slightly elevated plasma aspartate aminotransferase, and increased plasma glucose concentration compared to controls. The reduced protein level was not supported by an adverse effect on plasma albumin so was not considered to be toxicologically significant. The increased albumin/globulin ratio was thought to be due to a low control mean value. The increased plasma aspartate aminotransferase could not be associated with an adverse effect on a target organ or pathway, and was thought to have arisen by chance. All individual values for plasma glucose concentration in high-dose males were within the normally expected range, so were not considered to be of toxicological importance.
Levels of plasma creatinine were slightly, but significantly, reduced in females given 150 mg/kg bw/day, and plasma inorganic phosphorus levels were slightly increased. As the plasma creatinine change was not indicative of a toxic effect, and no concomitant change in plasma calcium was seen for the phosphorus findings, neither effect was considered toxicologically significant.
ORGAN WEIGHTS: See table 5 for details.
Increased absolute and relative kidney weights seen in females given 150 mg/kg bw/day, compared to controls. Findings not considered to be of toxicological relevance were: slight decrease in absolute, but not relative, liver weight in males given 150 mg/kg bw/day; increased absolute brain and ovary weights in females given 1.5 or 15 mg/kg bw/day, but not at 150 mg/kg bw/day (i.e. could not be related to dose).
GROSS PATHOLOGY:
One male given 150 mg/kg bw/day showed pallor of the liver, kidneys and glandular gastric epithelium. One female showed reddening of the glandular gastric epithelium. Findings not considered to be of toxicological significance were: an enlarged right testis in one male given 150 mg/kg bw/day and a small right testis in one male given 1.5 mg/kg bw/day (in the absence of histopathological data suggesting the testes as target organs); hydronephrosis of the kidney seen in one control and one 15 mg/kg bw/day female (a common condition for laboratory rats of this age and strain).
HISTOPATHOLOGY: NON-NEOPLASTIC: See table 6 for details.
Hepatic, splenic, renal and gastric abnormalities seen. Reduced glycogen type hepatocyte vacuolisation, and reduced splenic Perl's positive haemosiderin pigment accumulation seen in males and females given 150 mg/kg bw/day. The latter effect was also "probably" seen in females given 15 mg/kg bw/day. Deposits of Perl's negative pigment found in the renal proximal tubular epithelium of males and females given 150 mg/kg bw/day. Numbers of mucus-secreting Goblet cells were increased in the glandular gastric mucosa of males and females given 150 mg/kg bw/day and in one male given 15 mg/kg bw/day, with associated mucosal and sub-mucosal inflammatory cell infiltrates and mucosa ulceration in some cases.
A draft commentary on the report (Harleman, 1997) describes the reduced pigment deposition in females given 15 mg/kg bw/day as "slight" and notes that the "degree of pigment deposition in the spleen varies marked in rats". The commentary goes onto say that the "absence of pigment deposition is indicative of a toxicologic effect", whereas "slight variations of pigment deposition are normal and do not have any physicological, pathological, or toxicological significance". The findings are not considered indicative of a systemic adverse effect in this group. Findings in the stomach were considered indicative of local irritation, and not systemic toxicity.
HISTORICAL CONTROL DATA (if applicable): Available.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 15 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: histopathology (treatment-related hepatic, splenic, renal and gastric abnormalities)
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table 3: Average body weights and body weight gains during 28 days of treatment (standard deviation in brackets)
Dose (mg/kg bw/day) |
Body Weights (g) |
|
Total Weight Gain |
||||
Week 0 |
Week 1 |
Week 2 |
Week 3 |
Week 4 |
g |
% of control |
|
|
Male |
||||||
0 |
204 |
258 |
299 |
331 |
364 |
160 |
100 |
1.5 |
204 |
258 |
303 |
341 |
373 |
169 |
106 |
15 |
189 |
241 |
284 |
313 |
339 |
150 |
94 |
150 |
197 |
250 |
287 |
297 |
329 |
132 |
83 |
|
Female |
||||||
0 |
161 |
181 |
198 |
216 |
232 |
71 |
100 |
1.5 |
155 |
175 |
198 |
213 |
227 |
72 |
101 |
15 |
161 |
187 |
209 |
229 |
246 |
85 |
120 |
150 |
165 |
186 |
206 |
219 |
236 |
71 |
100 |
Data obtained from pages (46-7) in the study report.
Table 4: Group mean haematological and blood chemistry values (standard deviation in brackets)
Doses (mg/kg bw/day) |
0 |
1.5 |
15 |
150 |
0 |
1.5 |
15 |
150 |
male |
female |
|||||||
Number of animals/group |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
Haematology(day 28) |
|
|
|
|
|
|
|
|
- RBC (1012/L) |
7.38 (0.25) |
7.40 |
7.26 |
6.16* |
7.20 |
7.14 |
7.14 |
7.22 |
- MCV (FL) |
57.2 |
57.4 |
58.6 |
54.4** |
56.5 |
56.9 |
57.2 |
55.9 |
- MCH (pg) |
20.4 (0.3) |
21* |
21* |
20 |
20.3 |
20.6 |
20.4 |
20.3 |
- MCHC (g/dL) |
35.7 |
36.5 |
35.9 |
36.8* |
36.0 |
36.2 |
35.7 |
36.4 |
- HCT (%) |
42.2 (1.2) |
42.5 |
42.5 (0.5) |
33.5 |
40.7 |
40.6 |
40.8 |
40.3 |
- HGB (g/dL) |
15.1 (0.6) |
15.5 |
15.2 |
12.3** |
14.6 |
14.7 |
14.6 |
14.7 |
- WBC (109/L) |
11.4 |
14.0 |
15.6 |
15.2 |
9.9 |
11.8 |
9.7 |
9.8 |
- Neut (109/L) |
2.77 |
3.62 |
3.36 |
3.06 |
2.49 |
2.49 |
2.29 |
3.26 |
- Lymph (109/L) |
8.41 |
10.30 |
11.82* |
11.90* |
7.25 |
9.09 |
7.18 |
6.23 |
- Mono (109/L) |
0.00 |
0.03 |
0.07 |
0.00 |
0.02 |
0.00 |
0.02 |
0.06 |
- Eos (109/L) |
0.24 |
0.10 |
0.33 |
0.26 |
0.14 |
0.22 |
0.17 |
0.29* |
- Bas (109/L) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
- CT (secs) |
27 |
26 |
28 |
27 |
27 |
27 |
26 |
26 |
- PLT (109/L) |
1074 |
1102 |
1012 |
1294 |
993 |
1020 |
1076 |
1180* |
- Retic (%) |
8 |
9 |
10 |
17 |
8 |
8 |
7 |
8 |
Blood chemistry(day 28) |
|
|
|
|
|
|
|
|
- urea (mg/dL) |
33 |
33 |
34 |
34 |
37 |
36 |
32 |
44 |
- glucose (mg/dL) |
141 |
145 |
143 |
168*** |
153 |
153 |
140 |
174 |
- total protein (g/dL) |
6.94 |
6.93 |
6.93 |
6.16** |
6.93 |
7.14 |
6.94 |
6.71 |
- albumin (g/dL) |
3.44 |
3.42 |
3.40 |
3.31 |
3.77 |
3.80 |
3.76 |
3.70 |
- A/G ratio |
0.99 |
0.99 |
0.98 |
1.17* |
1.19 |
1.14 |
1.18 |
1.23 |
- sodium (MMOL/L) |
143 |
142 |
143 |
143 |
144 |
145 |
145 |
144 |
- potassium (MMOL/L) |
5.02 |
5.18 |
4.94 |
4.77 |
4.76 |
4.70 |
4.81 |
5.06 |
- chloride (MMOL/L) |
106 |
105 |
107 |
105 |
108 |
109 |
108 |
107 |
- calcium (MMOL/L) |
2.69 |
2.66 |
2.69 |
2.64 |
2.68 |
2.70 |
2.71 |
2.66 |
- phosphorus (MMOL/L) |
2.69 |
2.78 |
2.84 |
2.90 |
2.29 |
2.35 |
2.29 |
2.68* |
- ASAT (IU/L) |
95 |
91 |
95 |
116* |
94 |
93 |
91 |
106 |
- ALAT (IU/L) |
84 |
78 |
83 |
82 |
76 |
63 |
60 |
62 |
- AP (IU/L) |
584 |
521 |
568 |
529 |
393 |
354 |
365 |
391 |
- creatinine (mg/dL) |
0.53 |
0.55 |
0.54 |
0.54 |
0.61 |
0.60 |
0.58 |
0.56* |
- bilirubin (mg/dL) |
0.11 |
0.11 |
0.11 |
0.12 |
0.10 |
0.09 |
0.10 |
0.10 |
- CHE (KU/L) |
0.15 |
0.16 |
0.15 |
0.15 |
0.75 |
0.83 |
0.89 |
0.73 |
Statistics: * P < 0.05 ** P < 0.01 *** P < 0.001
Applicant's summary and conclusion
- Conclusions:
- In a GLP guideline study (EU Method B.7), rats were gavaged with tetraamminepalladium(II) hydrogen carbonate for 28 days. A NOAEL of 15 mg/kg bw/day was obtained based on microscopic changes in the spleen in high-dose animals (150 mg/kg bw/day)
- Executive summary:
In a GLP study, performed in accordance with EU Method B.7, male and female rats were treated orally with tetraamminepalladium(II) hydrogen carbonate for 28 days.
Groups of Sprague-Dawley rats (5/sex) were given daily gavage administrations of tetraamminepalladium(II) hydrogen carbonate at 0 (distilled water), 1.5, 15 or 150 mg/kg bw/day for 28 days. Throughout the study, animals were observed daily for mortality and overt clinical signs of toxicity. Body weight and food and water consumption were monitored. At the end of the study, blood samples were taken for haematological and clinical chemistry assessments, and animals were killed and subject to gross necropsy. The major organs of all treated and control animals were weighed, and the adrenals, heart, kidney, liver, spleen, stomach and testes of high-dose and control animals were examined microscopically. Having been identified as possible target organs, the liver, spleen, kidney and stomach were subsequently examined microscopically in all treated and control animals.
No unscheduled deaths or treatment-related overt clinical signs of toxicity were seen over the course of the study. During study week 3, growth was reduced in high-dose males and females, and high dose males demonstrated reduced food consumption and food efficiency – but these effects were not seen during week 4. High-dose males demonstrated reduced haemoglobin, erythrocyte count, haematocrit and mean corpuscular volume, with two rats having unusually high reticulocyte counts. A slight but significant rise in eosinophil levels was seen in high-dose females. At necropsy, absolute and relative kidney weights were increased in high-dose females. One high-dose male had a pale liver, kidney and glandular gastric epithelium, while one high-dose female had a reddened glandular gastic epithelium. Numbers of mucus-secreting Goblet cells were increased in the glandular gastric mucosa of one male given 15 mg/kg bw/day, indicating a local irritant effect of treatment. Treatment-related microscopic changes were seen in the spleens of females given 15 mg/kg bw/day (slightly reduced splenic haemosiderin deposition), and in the liver, spleen, kidneys and stomach of males and females given 150 mg/kg bw/day.
A draft commentary on the report notes that the "degree of pigment deposition in the spleen varies marked in rats" and that the "absence of pigment deposition is indicative of a toxicologic effect". However, "slight variations of pigment deposition are normal and do not have any physiological, pathological, or toxicological significance". Therefore, the overall no-observed-adverse-effect level (NOAEL) was considered to be 15 mg/kg bw/day, with the critical effect being microscopic changes in the spleen (no haemosiderin deposition in 5/5 males and 2/5 females, compared to 0 controls) in high-dose animals. Changes seen in the stomach have been considered indicative of local irritation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.